Caribou Biosciences, Inc.
CRBU · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $143,606 | $422,918 | $381,831 | $909,371 |
| - Cash | $16,293 | $51,162 | $58,338 | $240,420 |
| + Debt | $26,487 | $27,108 | $27,746 | $259 |
| Enterprise Value | $153,800 | $398,864 | $351,239 | $669,210 |
| Revenue | $9,994 | $34,477 | $13,851 | $9,598 |
| % Growth | -71% | 148.9% | 44.3% | – |
| Gross Profit | $6,067 | $30,952 | $10,210 | $8,614 |
| % Margin | 60.7% | 89.8% | 73.7% | 89.7% |
| EBITDA | -$162,689 | -$112,534 | -$95,710 | -$65,610 |
| % Margin | -1,627.9% | -326.4% | -691% | -683.6% |
| Net Income | -$149,105 | -$102,070 | -$99,421 | -$66,923 |
| % Margin | -1,491.9% | -296.1% | -717.8% | -697.3% |
| EPS Diluted | -1.65 | -1.38 | -1.64 | -1.11 |
| % Growth | -19.6% | 15.9% | -47.7% | – |
| Operating Cash Flow | -$138,200 | -$93,291 | -$90,966 | -$32,519 |
| Capital Expenditures | -$6,505 | -$11,613 | -$6,454 | -$3,121 |
| Free Cash Flow | -$144,705 | -$104,904 | -$97,420 | -$35,640 |